ArticleCureus2025
The GOLD-PCP Study: Clinician Insights on Person-Centric Packaging Design of a Triple Fixed-Dose Combination in Type 2 Diabetes Care.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedication adherence remains a significant challenge in managing type 2 diabetes, particularly for patients on long-term polypharmacy. Fixed-dose combinations (FDCs) may improve adherence by reducing pill burden, while person-centric packaging (PCP) aims to enhance ease of use and identification. The GOLD-PCP study explored clinician perceptions of PCP's impact on adherence and treatment management in diabetes care.
methodsA cross-sectional survey was conducted with 262 clinicians from India who had been prescribing this FDC with PCP for at least six months. Clinician perceptions were assessed through a validated 12-item questionnaire administered following structured round-table meetings. Data were analyzed using descriptive statistics and Pearson's correlation in IBM Corp. Released 2021. IBM SPSS Statistics for Windows, Version 27. Armonk, NY: IBM Corp.
resultsClinicians perceived improvements in patient adherence (83.2%), therapy simplification (82.1%), and medication identification (82.0%). Most (80.9%) believed the FDC helped reduce pill burden. The floral PCP design was perceived as helpful in increasing patient preference (78.6%), reducing pharmacy substitution (80.1%), and lowering missed doses (80.2%). A strong correlation was observed between perceived pill burden reduction and perceived adherence improvement (r = 0.883, p < 0.001). LIMITATIONS: This study assessed clinician perceptions only and did not include direct patient-level adherence measurements, objective adherence data, or patient-reported outcomes.
conclusionClinicians perceived PCP as beneficial for adherence support and therapy management in type 2 diabetes. However, further patient-centered studies using objective adherence metrics are needed to validate these perceptions and determine causal relationships between packaging design and adherence outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.